Biomarker Strategy in the Clinical Development of Ferroptosis-Based Cancer Therapy

• Overview of FerroptoCure’s biomarker strategy to support the clinical development of ferroptosis-based cancer therapies
• Current progress and future direction in identifying biomarkers for pharmacodynamic response and clinical utility in refractory cancers such as TNBC

Speakers:

Yuji Otsuki

Chief Executive Officer

FerroptoCure